University Hospitals Leuven at ESMO 2026
Oct 23–27, 2026 Madrid, Spain ~37k attendees Website
University Hospitals Leuven takes part in 6 sessions at ESMO 2026 in Madrid. Its program centres on antibody-drug conjugates in gynaecological and breast cancers, including HER2-targeted conjugates across solid tumours and new targets for platinum-resistant ovarian cancer. Other sessions cover RAS and other mutation targets in upper gastrointestinal cancer and the role of surgery in penile cancer.
| Organization | ESMO 2026 Attendance |
|---|---|
University Hospitals Leuven Leuven, Belgium | |
Teaching hospital group of KU Leuven in Leuven, Belgium, with its main campus at Gasthuisberg. | Chair Sat Oct 24 08:30–10:00 Rapid oral 2: Gynaecological cancers Gynaecological cancers Abstract Sat Oct 24 09:24–09:36 Invited Discussant 1246RO and 1247RO Gynaecological cancers Satellite Sun Oct 25 19:25–19:45 Future Directions: Next‑Generation ADCs and Emerging Targets for Platinum-resistant Breast cancerGynaecological cancers Satellite Sun Oct 25 19:45–20:00 Connecting Experience, Potential, and Future Frontiers: Panel discussion and audience Q&A Breast cancerGynaecological cancers Chair Mon Oct 26 08:30–10:00 Navigating the wave of new therapies in gynaecologic cancers Gynaecological cancers Talk Mon Oct 26 09:00–09:15 Overview of RAS and other mutational targets Gastrointestinal cancers Talk Mon Oct 26 09:10–09:30 Present and future of ADC in gynaecological cancers Gynaecological cancers Talk Mon Oct 26 14:50–15:10 The surgical oncology point of view: Role of surgery of primary and LN Genitourinary cancers Satellite Mon Oct 26 19:00–19:20 Satellite Mon Oct 26 19:40–20:00 |
Instantly find 20 buyers from University Hospitals Leuven
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction